Overview

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Phase:
PHASE1
Details
Lead Sponsor:
SEED Therapeutics, Inc.